Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Corvus Pharmaceuticals Inc Market Cap
The Corvus Pharmaceuticals Inc (CRVS) share price is expected to increase by 53.61% over the next year. This is based on calculating the average 12-month share price estimate provided by 6 stock analysts who have covered CRVS. Price targets range from $3.5 at the low end to $12 at the high end. The current analyst consensus for CRVS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Corvus Pharmaceuticals Inc has a total of 6 Wall St Analyst ratings. There are 5 buy ratings, 1 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Corvus Pharmaceuticals Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of CRVS.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jeff Jones Oppenheimer | Outperform | $8 | Maintains | May 7, 2024 |
| Li Watsek Cantor Fitzgerald | Overweight | Reiterates | Apr 1, 2024 | |
| Graig Suvannavejh Mizuho | Neutral | $3.5 | Maintains | Mar 27, 2024 |
| Jeff Jones Oppenheimer | Outperform | $7 | Maintains | Mar 20, 2024 |
| Li Watsek Cantor Fitzgerald | Overweight | $4 | Reiterates | Sep 7, 2023 |
| Mara Goldstein Mizuho | Neutral | $3.5 | Reiterates | Jun 16, 2023 |
| Aydin Huseynov Ladenburg Thalmann | Buy | $10 | Maintains | May 30, 2023 |
| Li Watsek Cantor Fitzgerald | Overweight | $4 | Maintains | May 9, 2023 |
| Mara Goldstein Mizuho | Neutral | $3.5 | Reiterates | Mar 30, 2023 |
| Aydin Huseynov Ladenburg Thalmann | Buy | $2 | Initiates | Oct 7, 2022 |
| Li Watsek Cantor Fitzgerald | Overweight | $8 | Maintains | Dec 3, 2021 |
| Roger Song Jefferies | Buy | $8 | Initiates | Dec 1, 2021 |
| Mara Goldstein Mizuho | Neutral | $3.5 | Maintains | Aug 3, 2021 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $6 | Maintains | Jul 16, 2021 |
Cantor Fitzgerald | Overweight | Initiates | May 27, 2021 | |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $9.5 | Maintains | Mar 26, 2021 |
| Mara Goldstein Mizuho | Neutral | $4 | Downgrade | Feb 10, 2021 |
HC Wainwright & Co. | Buy | $12 | Maintains | Oct 6, 2020 |
Wedbush | Outperform | $8 | Maintains | Mar 13, 2020 |
HC Wainwright & Co. | Buy | Initiates | Mar 10, 2020 |
When did it IPO
2016
Staff Count
28
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Richard A. Miller M.D.
Market Cap
$256.5M
In 2023, CRVS generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CRVS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 03 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - BURLINGAME, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held in New York from September 9-11, 2024. The Company's presentation will be on Tuesday, September 10 at 12:00pm ET.
Tue, 03 Sep 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Corvus Pharmaceuticals' lead candidate, Soquelitinib, is advancing towards a Phase 3 trial for PTCL, set to begin in September 2024. Soquelitinib has shown a 26% Complete Response Rate [CRR] in early trials, more than double the current standard of care. The PTCL market, estimated at $500 million in the U.S., offers significant potential if Soquelitinib's Phase 3 trials are successful.
Fri, 09 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Richard Miller - Chief Executive Officer Leiv Lea - Chief Financial Officer Jeff Arcara - Chief Business Officer Jim Rosenbaum - Senior Vice President, Research Ben Jones - Senior Vice President, Regulatory and Pharmaceutical Sciences Conference Call Participants Li Watsek - Cantor Roger Song - Jefferies Aydin Huseynov - Ladenberg Jeff Jones - Oppenheimer Graig Suvannavejh - Mizuho Operator Good afternoon, everyone, and thank you for standing by. Welcome to the Corvus Pharmaceuticals Second Quarter 2024 Business Update and Financial Results Conference Call.
Tue, 06 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Early Results from Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Demonstrate Clinical Activity and Corresponding Changes in Cytokine Levels Consistent with ITK Inhibition Mechanism of Action
Wed, 31 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Thu, 01 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet need for patients with relapsed or refractory PTCL, an indication with poor overall outcomes and no approved drugs based on randomized trials BURLINGAME, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to soquelitinib for the treatment of adult patients with relapsed or refractory peripheral T cell lymphoma (PTCL) after at least two lines of systemic therapy.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
